Comparison and analysis of the efficacy of drug therapy for liver cancer

Abstract

Hepatocellular carcinoma (HCC) is a poor prognosis tumor when not accessible to potentially curative treatments such as surgical resection, thermal ablations or liver transplantation. Systemic cytotoxic chemotherapies have shown inconsistent clinical benefit. In 2007, sorafenib, a tyrosine kinase inhibitor (TKI), was the first systemic therapy able to significantly improve the outcome of HCC patients non-eligible for curative or loco-regional therapies, despite a modest tolerance and low tumor objective response rate (ORR). Among the newer TKIs approved after 2017, lenvatinib was the first to show a striking ORR and demonstrate non-inferiority vs. sorafenib in the first-line setting. Furthermore, phase 3 trials showed the benefit of other TKIs, regorafenib and cabozantinib, and the anti-angiogenic ramucirumab monoclonal antibody, in systemic second-line therapy. Immune checkpoint inhibitors targeting PD1, achieved striking tumor shrinkage in some patients in monotherapy, seeming to be associated with exciting outcomes. Unfortunately, this occurred in too few patients to improve the median overall survival. More recently, the combination of anti-angiogenic drugs targeting the liver microenvironment with PD-1/PD-L1 inhibitors, such as the combination of bevacizumab and atezolizumab, proved to be substantially effective in phase 3, and other combinations of PD-1/PD-L1 and CTLA-4 inhibitors or TKIs have raised a lot of hopes for the systemic treatment of HCC.

Keywords

Hepatocellular carcinoma / therapy / immune checkpoint inhibitors / tyrosine kinase inhibitors

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[2] Bruix J,Sherman M.Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma..Gastroenterology2016;150:835-53

[3] Merle P,Phelip J,Bronowicki J.Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial..Lancet Gastroenterol Hepatol2019;4:454-65

[4] Whitehead J.Stopping clinical trials by design..Nat Rev Drug Discov2004;3:973-7

[5] Vogel A,Chau I,Llovet J.Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up..Ann Oncol2018;29:iv238-55

[6] Llovet JM,Montaña X,Coll S.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial..Lancet2002;359:1734-9

[7] El-Khoueiry AB,Yau T,Kudo M.Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab in patients with advanced hepatocellular carcinoma: subanalysis of CheckMate-040..J Clin Oncol2018;36:475

[8] Yau T,Kim TY,Santoro A.Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: results from CheckMate-040..J Clin Oncol2019;37:4012

[9] Bruix J,Llovet JM,Lencioni R.Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference..J Hepatol2001;35:421-30

[10] Llovet JM,Mazzaferro V,Gane E.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[11] Kudo M,Qin S,Ikeda K.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial..Lancet2018;391:1163-73

[12] Bruix J,Merle P,Huang Y.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;389:56-66

[13] Abou-Alfa GK,Cheng AL,Rimassa L.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma..N Engl J Med2018;379:54-63

[14] Zhu AX,Yen C,Galle PR.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet Oncol2019;20:282-96

[15] Tovoli F,Negrini G,Ferrarini A.Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib..Eur Radiol2018;28:3611-20

[16] Finn RS,Ikeda M,Ducreux M.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma..N Engl J Med2020;382:1894-905

[17] Zhu AX,Edeline J,Ogasawara S.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial..Lancet Oncol2018;19:940-52

[18] Finn RS,Merle P,Bouattour M.Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial..J Clin Oncol2020;38:193-202

[19] El-Khoueiry AB,Yau T,Kudo M.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502

[20] Yau T,Finn RS,Mathurin P.CheckMate 459: a randomized, multi-center phase III study of nivolumab vs sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.2019;Barcelona (Spain)European-Society-for-Medical-Oncology (ESMO) Congress

[21] Llovet JM,Raoul JL,Kudo M.Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study..J Clin Oncol2013;31:3509-16

[22] Lencioni R,Torres F,Decaens T.Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC..J Hepatol2017;66:1166-72

[23] Kudo M,Qin SK,Ikeda K.Analysis of survival and objective response in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).2019;San FranciscoGastrointestinal Cancers Symposium (ASCO GI) Congress

[24] Bruix J,Nakajima K,Meinhardt G.Time to progression and response rate are not reliable surrogate endpoints for overall survival in hepatocellular carcinoma: an analysis from the phase 3 RESORCE trial.2018;San FranciscoAmerican Association for the Study of Liver Diseases (AASLD) Congress

[25] Llovet JM,Villanueva A.Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival..J Hepatol2019;70:1262-77

[26] Miller AB,Staquet M.Reporting results of cancer treatment..Cancer1981;47:207-14

[27] Zhu AX,Evans TR,Santoro A.SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma..J Clin Oncol2015;33:559-66

[28] Zhu AX,Assenat E,Kang YK.Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial..JAMA2014;312:57-67

[29] Zhu AX,Malfertheiner P,Kawazoe S.Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by child-pugh score..JAMA Oncol2017;3:235-43

[30] Rimassa L,Peck-radosavljevic M,Zagonel V.Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study..Lancet Oncol2018;19:682-93